|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1-2
|
|
pubmed:dateCreated |
2008-7-28
|
|
pubmed:abstractText |
The brain's resistance to ischemic injury can be transiently augmented by prior exposure to a sub-lethal stress stimulus, i.e. preconditioning. It has been reported that Toll-like receptors (TLRs) are involved in the preconditioning-induced protective effect against ischemic brain injury. In this study, we investigated the effect of preconditioning with a TLR2 specific ligand, Pam3CSK4, on focal cerebral ischemia/reperfusion (I/R) injury in mice. Pam3CSK4 was administered systemically 24 h before the mice were subjected to focal cerebral ischemia (1 h) followed by reperfusion. Cerebral infarct size was determined, blood brain barrier (BBB) permeability was evaluated, and expression of tight-junction proteins were examined after focal cerebral I/R. Results showed that pre-treatment with Pam3CSK significantly reduced brain infarct size (1.9+/-0.5% vs 9.4+/-2.2%) compared with the untreated I/R group. Pam3CSK4 pre-treatment also significantly reduced acute mortality (4.3% vs 24.2%), preserved neurological function (8.22+/-0.64 vs 3.91+/-0.57), and attenuated brain edema (84.61+/-0.08% vs 85.29+/-0.09%) after cerebral I/R. In addition, Pam3CSK4 pre-treatment preserved BBB function as evidenced by decreased leakage of serum albumin (0.528+/-0.026 vs 0.771+/-0.059) and Evans Blue (9.23+/-0.72 microg/mg vs 12.56+/-0.65 microg/mg) into brain tissue. Pam3CSK4 pre-treatment also attenuated the loss of the tight junction protein occludin in response to brain I/R injury. These results suggest that TLR2 is a new target of ischemic preconditioning in the brain and preconditioning with a TLR2 specific ligand will protect the brain from I/R injury.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-10350645,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-10366191,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-10426996,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-10686298,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-10950379,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-11744245,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-12535703,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-1332509,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-14505575,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-14962484,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-15236188,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-15335102,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-15914466,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-16020761,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-16259957,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-16741177,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-16953973,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-17016855,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-17303117,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-17408640,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-17481951,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-17513782,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-17548055,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-1759559,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-17884182,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-17986487,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-7709410,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-8042219,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-9067475,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-9183285,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-9237759,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-961382,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18585792-9731622
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0165-5728
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
13
|
|
pubmed:volume |
199
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
75-82
|
|
pubmed:dateRevised |
2011-5-20
|
|
pubmed:meshHeading |
pubmed-meshheading:18585792-Animals,
pubmed-meshheading:18585792-Blood-Brain Barrier,
pubmed-meshheading:18585792-Blotting, Western,
pubmed-meshheading:18585792-Brain Edema,
pubmed-meshheading:18585792-Brain Ischemia,
pubmed-meshheading:18585792-Capillary Permeability,
pubmed-meshheading:18585792-Cerebral Infarction,
pubmed-meshheading:18585792-Immunohistochemistry,
pubmed-meshheading:18585792-Ischemic Preconditioning,
pubmed-meshheading:18585792-Ligands,
pubmed-meshheading:18585792-Lipopeptides,
pubmed-meshheading:18585792-Male,
pubmed-meshheading:18585792-Membrane Proteins,
pubmed-meshheading:18585792-Mice,
pubmed-meshheading:18585792-Peptides,
pubmed-meshheading:18585792-Reperfusion Injury,
pubmed-meshheading:18585792-Toll-Like Receptor 2
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Preconditioning with a TLR2 specific ligand increases resistance to cerebral ischemia/reperfusion injury.
|
|
pubmed:affiliation |
Department of Surgery, East Tennessee State University, Johnson City, TN 37614, United States.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, N.I.H., Extramural
|
